These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Ginns EI; Mak SK; Ko N; Karlgren J; Akbarian S; Chou VP; Guo Y; Lim A; Samuelsson S; LaMarca ML; Vazquez-DeRose J; Manning-Boğ AB Mol Genet Metab; 2014 Feb; 111(2):152-62. PubMed ID: 24388731 [TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. Aerts JM; Van Weely S; Boot R; Hollak CE; Tager JM J Inherit Metab Dis; 1993; 16(2):288-91. PubMed ID: 8411983 [No Abstract] [Full Text] [Related]
10. The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers. Toffoli M; Smith L; Schapira AHV J Neurochem; 2020 Jul; 154(1):11-24. PubMed ID: 31965564 [TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases. Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096 [TBL] [Abstract][Full Text] [Related]
12. [Gaucher disease]. Eto Y Nihon Rinsho; 2001 Mar; 59 Suppl 3():317-21. PubMed ID: 11347084 [No Abstract] [Full Text] [Related]
13. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410 [TBL] [Abstract][Full Text] [Related]
14. Pathological looping in the synucleinopathies: investigating the link between Parkinson's disease and Gaucher disease. Kinghorn KJ Dis Model Mech; 2011 Nov; 4(6):713-5. PubMed ID: 22065839 [TBL] [Abstract][Full Text] [Related]
15. Saposin C protects glucocerebrosidase against α-synuclein inhibition. Yap TL; Gruschus JM; Velayati A; Sidransky E; Lee JC Biochemistry; 2013 Oct; 52(41):7161-3. PubMed ID: 24070323 [TBL] [Abstract][Full Text] [Related]
16. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Meivar-Levy I; Horowitz M; Futerman AH Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):377-82. PubMed ID: 7980395 [TBL] [Abstract][Full Text] [Related]
17. Gaucher disease: insights from a rare Mendelian disorder. Sidransky E Discov Med; 2012 Oct; 14(77):273-81. PubMed ID: 23114583 [TBL] [Abstract][Full Text] [Related]
18. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. Xilouri M; Brekk OR; Stefanis L Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease. Wei J; Takamatsu Y; Wada R; Fujita M; Ho G; Masliah E; Hashimoto M Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33672048 [TBL] [Abstract][Full Text] [Related]
20. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Marshall J; McEachern KA; Kyros JA; Nietupski JB; Budzinski T; Ziegler RJ; Yew NS; Sullivan J; Scaria A; van Rooijen N; Barranger JA; Cheng SH Mol Ther; 2002 Aug; 6(2):179-89. PubMed ID: 12161184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]